WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Outrage as Tesla starts shipping $3,000 Cybertruck tent that looks nothing like as advertisedI lifted 200kg weights two days before giving birthI lifted 200kg weights two days before giving birthMore than 200 US chemical plants must reduce toxic emissions under new EPA ruleCrew abandon BritishCrew abandon BritishChildren addicted to tech including smartphones are more at risk of psychosis, study suggestsMy friend turned up to my wedding as a surprise, took four pizzas and had sex with my sisterSweet or savory? This is what your taste in snacks says about you, according to scienceThe Aucklanders who refuse to use food scrap bins
2.7803s , 6605.5703125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Issue news portal